All In Biotech

Drug Trial Radar · NCT05266807

Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence

Fecal Microbiota Transplantation Versus Vancomycin or Fidaxomicin in Clostridioides Difficile Infection First Episode or First Recurrence: A Randomized Controlled, Open-label, Multicenter Phase III Clinical Trial

Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Mar 15, 2023

Primary completion

Apr 1, 2027

Study completion Jan 31, 2028

Sponsor

Lead sponsor
Benoit GueryAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The clinical trial aims to evaluate the efficacy of fecal microbiota transplantation (FMT) after standard of care treatment (either vancomycin or fidaxomicin) vs the pragmatic use of standard of care treatment (either vancomycin or fidaxomicin) in severe and non-severe first episode and first recurrence of Clostridioides difficile infection (CDI). Experimental arm: antibiotic treatment (vancomycin or fidaxomicin as initially prescribed per SoC continued for 10 days) followed by FMT by oral capsules (one FMT, i.e. 20 FMT capsules given on 2 consecutive days, and followed by a 2nd FMT in severe CDI). Control Arm: vancomycin or fidaxomicin as initially prescribed per SoC continued for 10 days.

Conditions

  • Clostridioides Difficile Infection

Interventions

  • oral capsulized Fecal Microbiota TransplantationDrug

    FMT will be administered per os in the form of capsules containing faeces from a healthy donor. Capsules are manufactured at the CHUV pharmacy (University Hospital of Lausanne, Switzerland)

  • Vancomycin or FidaxomicinDrug

    Vancomycin or Fidaxomicin per os as initially prescribed per SoC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sustained clinical cure rateTime frame: 8 weeks after study treatment completion

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Universitätsspital

    Basel, Basel, Switzerland · Recruiting

  • Inselspital Bern

    Bern, Canton of Bern, Switzerland · Recruiting

  • HFR Fribourg - Hôpital cantonal

    Fribourg, Canton of Fribourg, Switzerland · Recruiting

  • Hirslanden Klinik St Anna

    Lucerne, Canton of Lucerne, Switzerland · Recruiting

  • Kantonsspital St Gallen, HOCH

    Sankt Gallen, Canton of St. Gallen, Switzerland · Recruiting

  • CHUV

    Lausanne, Canton of Vaud, Switzerland · Recruiting

  • Universitätsspital Zürich

    Zurich, Canton of Zurich, Switzerland · Recruiting

  • Institut central des hôpitaux

    Sion, Valais, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.